A Six-Month Study of Growth and Energy Expenditure in Children with Cystic Fibrosis Taking a Pulmonary Inhalation Medication (rhDNase)

Ellen B. Fung, Elizabeth M. Barden, Babette S. Zemel, Virginia A. Stallings, Barbara T. Heinrich, Thomas Scanlin, Dror Wasserman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To characterize the effects of recombinant human deoxyribonuclease (rhDNase) on growth velocity, body composition, resting energy expenditure (REE) and food intake in children with cystic fibrosis (CF). Methods: A prospective, six-month pilot study was conducted in twenty-one subjects with CF (twelve male, nine female, ages 11.5±3.1 years) measured at baseline, two and six months post-baseline. Repeated measures ANOVA was used to examine the change in variables across time. Results: The majority (75%) of subjects had minimal lung disease at baseline (FEV1: 80%–119% predicted). As expected for growing children, weight and height gains (1.6 kg and 2.5 cm) were observed between baseline and six months (p=0.0001). No change was observed in weight z-scores from six months prior to initiation of rhDNase therapy to six months post, though a significant decline (p=0.049) in Ht z-score was observed over this twelve-month period. Triceps skinfolds and mid-arm muscle circumference increased from baseline to six months (p<0.01); respective z-scores remained stable. Energy intake remained constant during the period it was studied from baseline to two months of therapy: 120%±27% RDA. REE, though slightly elevated compared to healthy children (baseline 106%±8% predicted), remained stable throughout the study and at a level which may be expected for children with minimal lung disease. A trend (p=0.057) towards a decrease in the number of subjects requiring hospitalization for pulmonary exacerbations during the trial period was observed. Conclusions: In summary, these pilot data from younger children with milder CF-related lung disease do not confirm anecdotal reports of improved rate of weight gain, caloric intake or decreases in the elevated REE. Future research might focus on documentation of the possible nutritional effects of rhDNase in clinical trials of children with more severe lung disease.

Original languageEnglish (US)
Pages (from-to)330-338
Number of pages9
JournalJournal of the American College of Nutrition
Volume18
Issue number4
DOIs
StatePublished - Aug 1 1999

Fingerprint

Deoxyribonucleases
Cystic Fibrosis
Inhalation
Energy Metabolism
Lung
Lung Diseases
Growth
Energy Intake
Weight Gain
Body Composition
Documentation
Analysis of Variance
Hospitalization
Eating
Clinical Trials
Weights and Measures
Muscles
Therapeutics

All Science Journal Classification (ASJC) codes

  • Nutrition and Dietetics
  • Medicine (miscellaneous)

Keywords

  • Cystic fibrosis
  • Dietary intake
  • Growth
  • Pulmonary function
  • Pulmozyme®
  • Resting energy expenditure
  • RhDNase

Cite this

Fung, Ellen B. ; Barden, Elizabeth M. ; Zemel, Babette S. ; Stallings, Virginia A. ; Heinrich, Barbara T. ; Scanlin, Thomas ; Wasserman, Dror. / A Six-Month Study of Growth and Energy Expenditure in Children with Cystic Fibrosis Taking a Pulmonary Inhalation Medication (rhDNase). In: Journal of the American College of Nutrition. 1999 ; Vol. 18, No. 4. pp. 330-338.
@article{7ec3c6141d174c7985380b9e20c4e7be,
title = "A Six-Month Study of Growth and Energy Expenditure in Children with Cystic Fibrosis Taking a Pulmonary Inhalation Medication (rhDNase)",
abstract = "Objective: To characterize the effects of recombinant human deoxyribonuclease (rhDNase) on growth velocity, body composition, resting energy expenditure (REE) and food intake in children with cystic fibrosis (CF). Methods: A prospective, six-month pilot study was conducted in twenty-one subjects with CF (twelve male, nine female, ages 11.5±3.1 years) measured at baseline, two and six months post-baseline. Repeated measures ANOVA was used to examine the change in variables across time. Results: The majority (75{\%}) of subjects had minimal lung disease at baseline (FEV1: 80{\%}–119{\%} predicted). As expected for growing children, weight and height gains (1.6 kg and 2.5 cm) were observed between baseline and six months (p=0.0001). No change was observed in weight z-scores from six months prior to initiation of rhDNase therapy to six months post, though a significant decline (p=0.049) in Ht z-score was observed over this twelve-month period. Triceps skinfolds and mid-arm muscle circumference increased from baseline to six months (p<0.01); respective z-scores remained stable. Energy intake remained constant during the period it was studied from baseline to two months of therapy: 120{\%}±27{\%} RDA. REE, though slightly elevated compared to healthy children (baseline 106{\%}±8{\%} predicted), remained stable throughout the study and at a level which may be expected for children with minimal lung disease. A trend (p=0.057) towards a decrease in the number of subjects requiring hospitalization for pulmonary exacerbations during the trial period was observed. Conclusions: In summary, these pilot data from younger children with milder CF-related lung disease do not confirm anecdotal reports of improved rate of weight gain, caloric intake or decreases in the elevated REE. Future research might focus on documentation of the possible nutritional effects of rhDNase in clinical trials of children with more severe lung disease.",
keywords = "Cystic fibrosis, Dietary intake, Growth, Pulmonary function, Pulmozyme{\circledR}, Resting energy expenditure, RhDNase",
author = "Fung, {Ellen B.} and Barden, {Elizabeth M.} and Zemel, {Babette S.} and Stallings, {Virginia A.} and Heinrich, {Barbara T.} and Thomas Scanlin and Dror Wasserman",
year = "1999",
month = "8",
day = "1",
doi = "https://doi.org/10.1080/07315724.1999.10718872",
language = "English (US)",
volume = "18",
pages = "330--338",
journal = "Journal of the American College of Nutrition",
issn = "0731-5724",
publisher = "American College Of Nutrition",
number = "4",

}

A Six-Month Study of Growth and Energy Expenditure in Children with Cystic Fibrosis Taking a Pulmonary Inhalation Medication (rhDNase). / Fung, Ellen B.; Barden, Elizabeth M.; Zemel, Babette S.; Stallings, Virginia A.; Heinrich, Barbara T.; Scanlin, Thomas; Wasserman, Dror.

In: Journal of the American College of Nutrition, Vol. 18, No. 4, 01.08.1999, p. 330-338.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Six-Month Study of Growth and Energy Expenditure in Children with Cystic Fibrosis Taking a Pulmonary Inhalation Medication (rhDNase)

AU - Fung, Ellen B.

AU - Barden, Elizabeth M.

AU - Zemel, Babette S.

AU - Stallings, Virginia A.

AU - Heinrich, Barbara T.

AU - Scanlin, Thomas

AU - Wasserman, Dror

PY - 1999/8/1

Y1 - 1999/8/1

N2 - Objective: To characterize the effects of recombinant human deoxyribonuclease (rhDNase) on growth velocity, body composition, resting energy expenditure (REE) and food intake in children with cystic fibrosis (CF). Methods: A prospective, six-month pilot study was conducted in twenty-one subjects with CF (twelve male, nine female, ages 11.5±3.1 years) measured at baseline, two and six months post-baseline. Repeated measures ANOVA was used to examine the change in variables across time. Results: The majority (75%) of subjects had minimal lung disease at baseline (FEV1: 80%–119% predicted). As expected for growing children, weight and height gains (1.6 kg and 2.5 cm) were observed between baseline and six months (p=0.0001). No change was observed in weight z-scores from six months prior to initiation of rhDNase therapy to six months post, though a significant decline (p=0.049) in Ht z-score was observed over this twelve-month period. Triceps skinfolds and mid-arm muscle circumference increased from baseline to six months (p<0.01); respective z-scores remained stable. Energy intake remained constant during the period it was studied from baseline to two months of therapy: 120%±27% RDA. REE, though slightly elevated compared to healthy children (baseline 106%±8% predicted), remained stable throughout the study and at a level which may be expected for children with minimal lung disease. A trend (p=0.057) towards a decrease in the number of subjects requiring hospitalization for pulmonary exacerbations during the trial period was observed. Conclusions: In summary, these pilot data from younger children with milder CF-related lung disease do not confirm anecdotal reports of improved rate of weight gain, caloric intake or decreases in the elevated REE. Future research might focus on documentation of the possible nutritional effects of rhDNase in clinical trials of children with more severe lung disease.

AB - Objective: To characterize the effects of recombinant human deoxyribonuclease (rhDNase) on growth velocity, body composition, resting energy expenditure (REE) and food intake in children with cystic fibrosis (CF). Methods: A prospective, six-month pilot study was conducted in twenty-one subjects with CF (twelve male, nine female, ages 11.5±3.1 years) measured at baseline, two and six months post-baseline. Repeated measures ANOVA was used to examine the change in variables across time. Results: The majority (75%) of subjects had minimal lung disease at baseline (FEV1: 80%–119% predicted). As expected for growing children, weight and height gains (1.6 kg and 2.5 cm) were observed between baseline and six months (p=0.0001). No change was observed in weight z-scores from six months prior to initiation of rhDNase therapy to six months post, though a significant decline (p=0.049) in Ht z-score was observed over this twelve-month period. Triceps skinfolds and mid-arm muscle circumference increased from baseline to six months (p<0.01); respective z-scores remained stable. Energy intake remained constant during the period it was studied from baseline to two months of therapy: 120%±27% RDA. REE, though slightly elevated compared to healthy children (baseline 106%±8% predicted), remained stable throughout the study and at a level which may be expected for children with minimal lung disease. A trend (p=0.057) towards a decrease in the number of subjects requiring hospitalization for pulmonary exacerbations during the trial period was observed. Conclusions: In summary, these pilot data from younger children with milder CF-related lung disease do not confirm anecdotal reports of improved rate of weight gain, caloric intake or decreases in the elevated REE. Future research might focus on documentation of the possible nutritional effects of rhDNase in clinical trials of children with more severe lung disease.

KW - Cystic fibrosis

KW - Dietary intake

KW - Growth

KW - Pulmonary function

KW - Pulmozyme®

KW - Resting energy expenditure

KW - RhDNase

UR - http://www.scopus.com/inward/record.url?scp=0032811674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032811674&partnerID=8YFLogxK

U2 - https://doi.org/10.1080/07315724.1999.10718872

DO - https://doi.org/10.1080/07315724.1999.10718872

M3 - Article

VL - 18

SP - 330

EP - 338

JO - Journal of the American College of Nutrition

JF - Journal of the American College of Nutrition

SN - 0731-5724

IS - 4

ER -